The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease.

@article{Karl2017TheTP,
  title={The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease.},
  author={T. Karl and B. Garner and David Cheng},
  journal={Behavioural pharmacology},
  year={2017},
  volume={28 2 and 3-Spec Issue},
  pages={
          142-160
        }
}
Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive loss of cognition. Over 35 million individuals currently have AD worldwide. Unfortunately, current therapies are limited to very modest symptomatic relief. The brains of AD patients are characterized by the deposition of amyloid-β and hyperphosphorylated forms of tau protein. AD brains also show neurodegeneration and high levels of oxidative stress and inflammation. The phytocannabinoid… Expand
Targeting Inflammatory Pathways in Alzheimer’s Disease: A Focus on Natural Products and Phytomedicines
TLDR
It is suggested that it is crucial for both the pharmacological and complementary medicine industries to conduct and fund studies to significantly advance the field of anti-inflammatory drugs and phytomedicines, as it is not yet clear if the active compounds reach an effective concentration in the brain or if they can slow down AD progression in long-term trials. Expand
Cannabidiol in Neurological and Neoplastic Diseases: Latest Developments on the Molecular Mechanism of Action
TLDR
The potential beneficial effects of CBD for Alzheimer’s disease, epilepsy, multiple sclerosis, and neurological cancers are discussed and the different mechanisms of action of CBD are disclosed. Expand
Chronic Treatment with 50 mg/kg Cannabidiol Improves Cognition and Moderately Reduces Aβ42 Levels in 12-Month-Old Male AβPPswe/PS1ΔE9 Transgenic Mice.
TLDR
It is demonstrated that therapeutic-like effects of 50 mg/kg CBD on social recognition memory and spatial learning deficits in AβPPxPS1 mice are accompanied by moderate brain region-specific reductions in insoluble Aβ40 levels. Expand
Cannabidiol (CBD) enhanced the hippocampal immune response and autophagy of APP/PS1 Alzheimer's mice uncovered by RNA-seq.
TLDR
It is illustrated that CBD may improve the pathological process of AD by enhancing immune system response and autophagy pathway by enhancing auto-inhibitory mechanisms in hippocampal neurons. Expand
Nature’s Derivative(s) as Alternative Anti-Alzheimer’s Disease Treatments
TLDR
The use of such alternative therapies borrowed from Ayurveda, traditional Chinese practices, meditation, and exercising for AD treatment will be a stepping-stone in preventing, treating, curing, or managing the disease. Expand
Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.
TLDR
A selected number of pre-clinical and clinical studies, examining the effects of CBD in neuropsychiatric disorders, found CBD to be safe, well-tolerated and efficacious in mitigating the symptoms associated with several types of seizure disorders and childhood epilepsies. Expand
Medium-Dose Chronic Cannabidiol Treatment Reverses Object Recognition Memory Deficits of APP Swe /PS1ΔE9 Transgenic Female Mice
TLDR
Medium-dose CBD appears to have therapeutic value for the treatment of particular behavioral impairments present in AD patients, and the molecular mechanisms behind CBD’s beneficial properties for AD transgenic mice are considered. Expand
The (Poly)Pharmacology of Cannabidiol in Neurological and Neuropsychiatric Disorders: Molecular Mechanisms and Targets
TLDR
A comprehensive and up-to-date overview of the molecular basis underlying the therapeutic effects of CBD involved in the treatment of neurological and neuropsychiatric disorders is provided. Expand
Modulation of Astrocyte Activity by Cannabidiol, a Nonpsychoactive Cannabinoid
TLDR
The collected data shows that increased astrocyte activity is suppressed in the presence of CBD in models of ischemia, Alzheimer-like and Multiple-Sclerosis-like neurodegenerations, sciatic nerve injury, epilepsy, and schizophrenia. Expand
Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies
TLDR
The goal of this review is to provide an outline of the endocannabinoid system, including endoc cannabinoidsoid metabolizing pathways, and will progress to a more in-depth discussion of the therapeutic interventions by endoc cannabinoidoids in various neurological disorders. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 174 REFERENCES
The therapeutic potential of the endocannabinoid system for Alzheimer's disease
TLDR
Future research should focus on the evaluation of the effects of manipulations to the endocannabinoid system in established animal models for AD, combined with early-phase studies in humans. Expand
Cannabidiol: A Promising Drug for Neurodegenerative Disorders?
TLDR
Among Cannabis compounds, cannabidiol (CBD), which lacks any unwanted psychotropic effect, may represent a very promising agent with the highest prospect for therapeutic use. Expand
Alzheimer's disease; taking the edge off with cannabinoids?
TLDR
Cannabinoids offer a multi‐faceted approach for the treatment of Alzheimer's disease by providing neuroprotection and reducing neuroinflammation, whilst simultaneously supporting the brain's intrinsic repair mechanisms by augmenting neurotrophin expression and enhancing neurogenesis. Expand
Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation
TLDR
It is shown that senile plaques in AD patients express cannabinoid receptors CB1 and CB2, together with markers of microglial activation, and that CB1-positive neurons, present in high numbers in control cases, are greatly reduced in areas of microgoo activation. Expand
A molecular link between the active component of marijuana and Alzheimer's disease pathology.
TLDR
It is demonstrated that the active component of marijuana, Delta9-tetrahydrocannabinol (THC), competitively inhibits the enzyme acetylcholinesterase (AChE) as well as prevents AChE-induced amyloid beta-peptide aggregation, the key pathological marker of Alzheimer's disease. Expand
The Endocannabinoid System and Alzheimer’s Disease
TLDR
Data obtained in vitro, as well as in animal models for this disease and in human samples seem to corroborate the notion that the activation of the ECS, through the use of agonists or by enhancing the endogenous cannabinoid tone, may induce beneficial effects on the evolution of this disease. Expand
The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disorder. A massive accumulation of β-amyloid (Aβ) peptide aggregates has been proposed as pivotal event in AD. Aβ-inducedExpand
Targeting microglia for the treatment of Alzheimer’s disease
TLDR
A hopeful approach to a disease-modifying treatment of AD is to administer agents that inhibit the inflammatory stimulation of microglia or successfully convert them to an M2 state, however, any such treatment must be started early in the disease. Expand
Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice
TLDR
It is shown that chronically administered cannabinoid showed marked beneficial effects concomitant with inflammation reduction and increased Aβ clearance. Expand
Inflammation and aging: can endocannabinoids help?
TLDR
The basis for the manipulation of the endocannabinoid system in the brain in combination with existing treatments for Alzheimer's disease will be discussed in this review. Expand
...
1
2
3
4
5
...